Alterity Therapeutics Ltd (ATHE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.88 (+3.47%), Market cap $0.08B, 52-week low–high $2.92 ~ $6.55.
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compo
Financial statements, price targets, institutional (13F) holdings and related news for Alterity Therapeutics Ltd are updated in real time on BlackAll Trade.
Alterity Therapeutics Ltd trades at $3.88 (+3.47%). Real-time quotes and charts are available on BlackAll Trade.
Alterity Therapeutics Ltd has a market cap of about $0.08B.
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lea